NasdaqGM:SMMTBiotechs
Should Jefferies’ Downgrade and Ivonesimab Focus Shape Summit Therapeutics’ (SMMT) Risk‑Reward Profile?
Jefferies recently downgraded Summit Therapeutics to Hold after the company reported a fourth-quarter 2025 EPS miss but highlighted a strong cash position and advancing clinical programs for its lead asset, ivonesimab.
Summit is broadening its late-stage oncology pipeline with new trials in metastatic colorectal cancer and head and neck squamous cell carcinoma, underscoring robust clinical interest and rapid patient enrollment.
Next, we will examine how Jefferies’ downgrade and the...